MiR-506 Inhibits Multiple Targets in the Epithelial-to-mesenchymal Transition Network and is Associated with Good Prognosis in Epithelial Ovarian Cancer
Authors
Affiliations
Extensive investigations have shown that miRNAs are important regulators of epithelial-to-mesenchymal transition (EMT), mainly targeting the transcriptional repressors of E-cadherin (E-cad). Less is known about the post-transcriptional regulation of vimentin or N-cadherin (N-cad) in EMT. Our previous study identified miR-506 as a key EMT inhibitor through directly targeting the E-cad transcriptional repressor SNAI2. In this study, we provide evidence that miR-506 simultaneously suppresses vimentin and N-cad. The knockdown of vimentin using siRNA reversed EMT, suppressed cell migration and invasion, and increased E-cad expression on the cell membrane in epithelial ovarian cancer (EOC) cells. In a set of tissue microarrays that included 204 EOCs of all major subtypes (eg serous, endometrioid, clear cell, and mucinous), miR-506 was positively correlated with E-cad and negatively correlated with vimentin and N-cad in all subtypes of EOC. A high level of miR-506 was positively associated with early FIGO stage and longer survival in EOC. Introduction of miR-506, mediated by nanoparticle delivery, in EOC orthotopic mouse models resulted in decreased vimentin, N-cad, and SNAI2 expression and increased E-cad expression; it also suppressed the dissemination of EOC cells. Thus, miR-506 represents a new class of miRNA that regulates both E-cad and vimentin/N-cad in the suppression of EMT and metastasis.
Pirrotta S, Masatti L, Bortolato A, Corra A, Pedrini F, Aere M NAR Genom Bioinform. 2024; 6(4):lqae138.
PMID: 39363890 PMC: 11447528. DOI: 10.1093/nargab/lqae138.
Khaboushan A, Salimian S, Mehraban S, Bahramy A, Zafari N, Kajbafzadeh A Heliyon. 2024; 10(16):e35202.
PMID: 39253159 PMC: 11382180. DOI: 10.1016/j.heliyon.2024.e35202.
Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance.
Tabatabaee A, Nafari B, Farhang A, Hariri A, Khosravi A, Zarrabi A Cancer Metastasis Rev. 2023; 43(1):363-377.
PMID: 38012357 DOI: 10.1007/s10555-023-10154-7.
Zheng C, Li R, Zheng S, Fang H, Xu M, Zhong L Cancer Sci. 2023; 114(12):4747-4762.
PMID: 37817462 PMC: 10728003. DOI: 10.1111/cas.15989.
Rencuzogullari O, Arisan E Turk J Biol. 2023; 46(5):342-360.
PMID: 37529006 PMC: 10387936. DOI: 10.55730/1300-0152.2622.